High-dose ifosfamide and mesna in advanced breast cancer
- 1 January 1990
- journal article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 26 (S1) , S91-S92
- https://doi.org/10.1007/bf00685432
Abstract
Thirty-two patients with metastatic breast cancer had previously been treated with chemotherapy (in cluding anthracyclines). They were included in a trial to receive 6 g/m3 ifosfamide, mixed with 6 g/m2 mesna in 1000 ml saline infusion, infused over 4 h. Therapy was repeated every 21 days; the dose was reduced by 50%. Twenty-eight patients could be evaluated. An average of 4.2 cycles (range 2–8) was applied. One patient (4%) showed complete remission. Ten patients (36%) had a partial response. Ten patients (36%) experienced SD and the remaining patients (25%) PD. We conclude that high-dose ifosfamide shows activity in this group of pretreated patients and merits further investigation.Keywords
This publication has 4 references indexed in Scilit:
- Ifosfamide-pharmacology, safety and therapeutic potentialCancer Treatment Reviews, 1985
- Chemotherapy of breast cancerMedical Oncology and Tumor Pharmacotherapy, 1984
- Chemotherapy of breast cancer: Current views and resultsInternational Journal of Radiation Oncology*Biology*Physics, 1983
- PREVENTION OF ISOPHOSPHAMIDE-INDUCED UROTHELIAL TOXICITY WITH 2-MERCAPTOETHANE SULPHONATE SODIUM (MESNUM) IN PATIENTS WITH ADVANCED CARCINOMAThe Lancet, 1980